Skip to main content
. 2013 Apr 24;6(1):130–134. doi: 10.3892/ol.2013.1317

Table III.

MGMT immunoreactivity in human gliomas.

Grade Immunonegative cases, n (%) Immunopositive cases, n (%)
I 6 (66.7) 3 (33.3)
II 29 (51.8) 27 (48.2)
III 22 (42.3) 30 (57.7)
IV 11 (31.4) 24 (68.6)

P>0.05 among grades I, II, III and IV (χ2 test). MGMT, O6-methylguanine-DNA methyltransferase.